VISIT THE RHONDA'S CLUB TABLE AT THE FOUNDATION FOR WOMEN'S CANCER WEEKEND, NOVEMBER 5-6

The Foundation for Women's Cancer (formerly Gynecologic Cancer Foundation) is coming to Washington to host a weekend of activities on Saturday, November 5 and Sunday, November 6, 2011. The Foundation will celebrate it's 20th anniversary with a full day of free seminars and a one-mile walk/8K run to raise awareness and crucial research funding to prevent, detect, treat and defeat cancers unique to women.

Three courses for survivors of cervical, ovarian and uterine cancer will be held at the Washington Marriott Metro Center (775 12th Street, NW) on Saturday, November 5. They're free, but in order to attend, you need to register at http://www.wcn.org/courses. Go to "2011 Survivor Course Schedule" in the middle of the page and click on the DC courses.

To join TEAM TEAL (our combined Rhonda’s Club and OCNA team) for the one-mile walk or 8K run on Sunday, register at http://www.gcfrace.com/index2.html and click on “join an existing team.” Look for our "TEAM TEAL" banner at the start of the race. All proceeds from the race will benefit the Foundation for Women's Cancer, which is dedicated to gynecologic cancer prevention, early detection and optimal treatment.

SURVIVOR EDUCATION PROGRAM

The Future of Ovarian & Gynecologic Cancer, presented by Dr. Michael V. Seiden, MD, PhD, President and CEO of Fox Chase Cancer Center, Philadelphia, PA, to Rhonda's Club on September 12, 2011.

Click on the image above to watch the video.

Click here to download slides accompanying Dr. Michael V. Seiden's presentation.

view our calendar of events >

MEDICAL NEWS

Ovarian Cancer Advocates Troubled by FDA Decision on Avastin and Breast Cancer
Posted by the Ovarian Cancer National Alliance (OCNA)

On November 18, the Food and Drug Administration (FDA) announced that it would remove metastatic breast cancer from the label for Avastin (bevacizumab). This decision follows recommendations made in June by the FDA Oncologic Drugs Advisory Committee. Responding to today’s decision, OCNA CEO Karen Orloff Kaplan, MSW, MPH, ScD, expressed concern that the removal of metastatic breast cancer from the Avastin label could negatively affect women with ovarian cancer, for whom the drug is used off-label.  read more >>

Chemotherapy Drug Shortages

Over the summer, the United States experienced shortages of more than 200 drugs, including chemotherapeutic agents, intravenous nutrition and anesthesia drugs. The vast majority of drugs in shortage were generic sterile injectibles. Many ovarian cancer patients are wondering what is being done to resolve this critical issue. For more information, visit OCNA’s website at www.ovariancancer.org/drug-shortages/

more resources >